Trials / Unknown
UnknownNCT04982432
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Gregor Jemec · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of oral administration of orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orismilast | Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-07-29
- Last updated
- 2021-09-28
Source: ClinicalTrials.gov record NCT04982432. Inclusion in this directory is not an endorsement.